Presentation of First Time Attenders at Lymphedema Clinics

Sponsor
Universitaire Ziekenhuizen Leuven (Other)
Overall Status
Completed
CT.gov ID
NCT03687749
Collaborator
University of Sydney (Other)
46
2
46.9
23
0.5

Study Details

Study Description

Brief Summary

The first aim of this research project is to identify what factors motivate patients to seek assessment for early lymphedema and further, to gain insight into the signs and symptoms of developing lymphedema and the concurrent physical measurements.

The second aim is to identify other sensory signs and symptoms and changes in body perception which may be perceived by the patient as reflective of lymphedema, and to identify to which degree they contribute to the patients' motivation to seek referral to lymphedema clinics.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    One of the most challenging morbidities after breast cancer treatment is lymphedema. Approximately 20% of women treated for breast cancer with axillary lymph node dissection will be diagnosed with lymphedema. Pre- and post-operatively, women are informed about changes suggestive of lymphedema and guided about seeking further assessment. The investigators presume that if symptoms occur, patients will seek assessment. However, it is unknown whether this is true or if those prospectively monitored present earlier for treatment, or whether other factors specifically drive patients to seek further assessment. Understanding the early experience and presentation of secondary lymphedema will improve patient education and detection programs.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    46 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Presentation of First Time Attenders at Lymphedema Clinics: Cross-sectional Study
    Actual Study Start Date :
    Feb 1, 2017
    Actual Primary Completion Date :
    Feb 1, 2020
    Actual Study Completion Date :
    Dec 31, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Women with breast cancer-related lymphedema

    Individuals with upper limb lymphedema developed after breast cancer treatment

    Healthy control subjects

    Healthy individuals without breast cancer-related lymphoedema.

    Outcome Measures

    Primary Outcome Measures

    1. Extracellular fluid in the arm [immediately after inclusion in the study]

      Bioimpedance spectroscopy (BIS) is a measurement tool used to determine the volume of extracellular fluid, of which lymph fluid is a component.

    2. Arm volume [immediately after inclusion in the study]

      Arm circumference measures are commonly used to diagnose and monitor lymphedema.

    3. Pitting [immediately after inclusion in the study]

      The pitting tests examines the responsiveness of tissue to pressure and can be used to help determine the stage of lymphedema.

    Secondary Outcome Measures

    1. Self-reported signs and symptoms of lymphedema [immediately after inclusion in the study]

      Norman questionnaire for early detection of lymphedema will be used; this validated questionnaire will allow us to determine the location and severity of the symptoms that the patients have experienced over the past three months as well as how much distress it has caused.

    2. Impairments in function, activity limitations, and participation restrictions of patients with arm lymphedema [immediately after inclusion in the study]

      Lymphoedema Functioning, Disability and Health questionnaire (Lymph-ICF): The Lymph-ICF is a reliable and valid questionnaire to assess impairments in function, activity limitations, and participation restrictions of patients with arm lymphedema.

    3. Global Health Status/Quality of Life Score [immediately after inclusion in the study]

      Health-related quality of life assessed with the generic QLQ-C30 and the disease-specific QLQ-BR23 questionnaire

    4. Body perception [immediately after inclusion in the study]

      The BATH CRPS body perception disturbances scale: to assess body perception disturbances in breast cancer patients.

    5. Pain intensity assessed with the Numeric Rating Scale [immediately after inclusion in the study]

      Numeric Rating Scale for maximal pain intensity during the past week.

    6. Prevalence of neuropathic pain [immediately after inclusion in the study]

      Measured with the Douleur Neuropathique en 4 questions (DN4)

    7. Tactile acuity (Two-point discrimination) [immediately after inclusion in the study]

      To assess body perception two-point discrimination will be assessed at both arms, the breasts and lateral trunk side.

    8. Mechanical detection and pain threshold [immediately after inclusion in the study]

      The lowest mechanical forces, applied to the skin using nylon monofilaments that the subject can 1) detect and 2) is perceived as painful) are tested at the upper limb and upper body region.

    9. Temporal summation [immediately after inclusion in the study]

      Detection of perceived temporal summation at the upper limb and upper body region tested using repeated 26g nylon monofilament stimulation.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • women after breast cancer (> 18 years) with unilateral axillary lymph node dissection or sentinel node biopsy; mastectomy (with or without autologous reconstruction) or wide excision of the tumor

    • able to give consent to participate in the research

    Exclusion Criteria:
    • patients under the age of 18 years

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Sydney, Faculty of Health Sciences Sydney New South Wales Australia 2006
    2 University Hospital Leuven Leuven Belgium 3000

    Sponsors and Collaborators

    • Universitaire Ziekenhuizen Leuven
    • University of Sydney

    Investigators

    • Principal Investigator: An De Groef, PhD, Universitaire Ziekenhuizen Leuven
    • Principal Investigator: Elizabeth Dylke, PhD, University of Sydney, Faculty of Health Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Universitaire Ziekenhuizen Leuven
    ClinicalTrials.gov Identifier:
    NCT03687749
    Other Study ID Numbers:
    • S59883
    First Posted:
    Sep 27, 2018
    Last Update Posted:
    Apr 30, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 30, 2021